# A Study in Healthy Men to Test How Different Doses of BI 474121 Are Taken up and How They Influence the Amount of a Molecular Messenger (cGMP) in the Spinal Fluid

> **NCT04672954** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Placebo
- **DRUG:** 2.5 milligram (mg) BI 474121
- **DRUG:** 10 milligram (mg) BI 474121
- **DRUG:** 20 milligram (mg) BI 474121
- **DRUG:** 40 milligram (mg) BI 474121

## Key facts

- **NCT ID:** NCT04672954
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-07
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-07-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04672954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04672954, "A Study in Healthy Men to Test How Different Doses of BI 474121 Are Taken up and How They Influence the Amount of a Molecular Messenger (cGMP) in the Spinal Fluid". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04672954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*